Flanvotumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Flanvotumab Usage And Synthesis

Uses

Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance[1].

References

[1] Khalil DN, et al. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 1;22(21):5204-5210. DOI:10.1158/1078-0432.CCR-16-1241

Flanvotumab(1188277-05-5)Related Product Information

• Glenzocimab
• Gresonitamab
• Feladilimab
• Rinucumab
• Avizakimab
• Vibecotamab
• Cadonilimab
• Prolgolimab
• Bafisontamab
• Tozorakimab